戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed estimated human half-life consistent with once daily dosing.
2 okinetic (PK) profile that was predictive of once-daily dosing.
3 t achieves stable plasma concentrations with once-daily dosing.
4 rol duration of action in vivo, suitable for once-daily dosing.
5 been discovered, with the hopes of achieving once-daily dosing.
6 lease formulation of tacrolimus designed for once-daily dosing.
7  elimination half-life (16-17 hours) support once-daily dosing.
8  the efficacy and safety of bosutinib 500 mg once-daily dosing.
9 inetic profile of BG9928 was consistent with once-daily dosing.
10 fold drug accumulation at steady-state after once-daily dosing.
11  three-fold drug accumulation after repeated once-daily dosing.
12 e inhibitor with a half-life that allows for once-daily dosing.
13 returned to baseline levels by 24 hours with once-daily dosing.
14 d exhibited a plasma half-life supportive of once-daily dosing.
15 action, potentially making them suitable for once-daily dosing.
16  a pharmacokinetic profile commensurate with once-daily dosing.
17         Chronic steroid use usually involves once-daily dosing, although weekly dosing in children ha
18 ose combinations (FDC) with the advantage of once daily dosing and improved tolerability and toxicity
19  low rates of CRB and TEs with advantages of once daily dosing and infrequent monitoring requirement.
20 PEP prescribing practices, likely due to its once-daily dosing and high tolerability.
21   DNL343 demonstrated a half-life supporting once-daily dosing and showed extensive CSF distribution.
22 ater bioavailability of LCP-Tacro allows for once-daily dosing and similar (AUC) exposure at a dose a
23 s that demonstrated properties indicative of once-daily dosing and superior potency against resistant
24           Ten women were assigned to receive once-daily dosing and ten were assigned to receive twice
25      Given a favorable tolerability profile, once-daily dosing, and evidence of clinically relevant b
26 ll tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial
27 d MK-0752, 21 patients received a continuous once-daily dosing at 450 and 600 mg; 17 were dosed on an
28 asma levels help to detect nonadherence, and once-daily dosing at night (which is possible with many
29 tacrolimus monotherapy with consolidation to once daily dosing by 6 months and once every other day d
30 NaC-transgenic mice to greater than 90% with once-daily dosing by inhalation.
31          The improvements in spirometry with once-daily dosing confirm the long duration of action of
32 was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma
33 e of thromboprophylaxis (heparin, enoxaparin once-daily dosing, early ambulation), hospital discharge
34 y reactions, superior resistance profile and once-daily dosing favours abacavir for African children,
35 than in the past, with lower pill burden and once-daily dosing frequency common.
36 , and those with once-daily versus more than once-daily dosing frequency.
37  bioavailability and prolonged exposures for once-daily dosing, good colonic absorption and a reliabl
38      At month 6, 90.5% of patients receiving once-daily dosing had maintained clinical remission, com
39     At month 12, 85.4% of patients receiving once-daily dosing had maintained clinical remission, com
40  robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model.
41 s of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advan
42 cal pharmacokinetic properties predictive of once daily dosing in humans.
43 irmed therapeutic rivaroxaban exposures with once-daily dosing in children with bodyweights of at lea
44 herapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients.
45 rameters in preclinical species that support once-daily dosing in humans.
46                           However, at 300 mg once daily dosing, it was not well tolerated in this pop
47                It is unclear whether the two once-daily dosing non-vitamin K antagonist oral anticoag
48                  In this study, the proposed once daily dosing of dolutegravir dispersible tablets pr
49 nducted with 43 subjects assigned to receive once daily dosing of either placebo (n = 21) or JNJ-4216
50  half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.
51 n cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616.
52 uction in asexual blood-stage parasites with once-daily dosing of 50 mg for 7 days.
53 cted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol
54                                              Once-daily dosing of delayed-release mesalamine at doses
55 ety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for us
56     In this randomized, double-masked trial, once-daily dosing of netarsudil 0.02% was effective, con
57 domized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be ef
58 y dosing (P=0.024) and 93.5% for patients on once-daily dosing (P=0.008).
59 n a higher serum hepcidin concentration than once-daily dosing (p=0.013).
60                             In six patients, once-daily dosing produced median serum concentrations a
61 of adverse effects or switch to the use of a once-daily dosing regimen due to compliance issues.
62 ort the concentration-dependent activity and once-daily dosing regimen of telavancin.
63 biological half-life of 10.5 h, suggesting a once-daily dosing regimen.
64 alternate pathways of outflow; the advent of once-daily dosing regimens improving patient compliance;
65  possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile
66 h human immunodeficiency virus (HIV) include once-daily dosing, simplification of co-treatment for tu
67 tion of BCR-ABL signaling activity following once-daily dosing suggested acute, potent inhibition of
68 over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.
69 In the fourth subgroup, those with more than once-daily dosing, the ICER was $2625/QALY.
70                                       Unlike once-daily dosing, twice-daily PAS maintained serum conc
71          Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in
72 izophrenia were randomly assigned to receive once-daily dosing with 10 mg of ABT-126, 25 mg of ABT-12
73                                Mice received once-daily dosing with amifostine (10-100 mg/kg, intrape
74 his study provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual
75             The PK profile was supportive of once-daily dosing with median peak plasma concentrations
76        The pharmacokinetics profile supports once-daily dosing, with evidence of pharmacodynamic and